DGIdb - SCN5A Gene Record

SCN5A 6331 Druggable Genome

Alternate Names:

6331
SODIUM VOLTAGE-GATED CHANNEL ALPHA SUBUNIT 5
SCN5A
CDCD2
CMD1E
CMPD2
HB1
HB2
HBBD
HH1
ICCD
IVF
LQT3
Nav1.5
PFHB1
SSS1
VF1
600163
10593
ENSG00000183873
OTTHUMG00000156166
PA304
Q14524
Voltage-gated sodium channel subunit alpha Nav1.5
Sodium channel protein type V subunit alpha
Sodium channel protein cardiac muscle subunit alpha
Sodium channel protein type 5 subunit alpha
SCN5A_HUMAN
SODIUM CHANNEL PROTEIN TYPE V ALPHA SUBUNIT (VOLTAGE-GATED SODIUM CHANNEL ALPHA SUBUNIT NAV1.5) (SODIUM CHANNEL PROTEIN, CARDIAC MUSCLE ALPHA-SUBUNIT) (HH1). [SOURCE:UNIPROT/SWISSPROT;ACC:Q14524]
Voltage-gated sodium channel alpha Nav1.5
T39716

Gene Info:

Initial Gene Query	Nav1.5
Counted Citations from 1950-2000	1178
Transmembrane Helix Count	22
Target Subclass	Channels
Target Subclass	Voltage_gated_ion_channels
Target Main Class	Transporters
Target Subclass	SodiumChannels
Interpro Acc	IPR005821
Interpro Type	Domain
Interpro Name	Ion transport domain
Uniprot Status	Swiss-Prot
Uniprot Evidence	1: Evidence at protein level
Human Readable Name	ION CHANNEL
Interpro Short Name	Ion_trans_dom
Human Readable Name	DRUGGABLE GENOME
Target Class	Transporters
Target Subclass	TC:1.A.1.10.3
Gene Biotype	PROTEIN_CODING

(9 More Sources)

Gene Categories: Category Details

CELL SURFACE
ION CHANNEL
DRUGGABLE GENOME

Publications:

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Lenkowski et al., 2004, Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin., Eur J Pharm Sci
Kamiya et al., 1991, A combination of inactivated sodium channel blockers causes competitive interaction on dV/dtmax of single ventricular myocytes., Cardiovasc. Res.
Sato et al., 1991, Aprindine blocks the sodium current in guinea-pig ventricular myocytes., Naunyn Schmiedebergs Arch. Pharmacol.
Swadron et al., 2004, A comparison of phenytoin-loading techniques in the emergency department., Acad Emerg Med
Mantegazza et al., 2010, Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders., Lancet Neurol
Liu et al., 2003, Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues., J. Gen. Physiol.
Viswanathan et al., 2001, Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes., Circulation
Ramos et al., 2004, State-dependent trapping of flecainide in the cardiac sodium channel., J. Physiol. (Lond.)
Benhorin et al., 2000, Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?, Circulation
Nagatomo et al., 2000, Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide., Mol. Pharmacol.
Priori et al., 2000, The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge., Circulation
Cerrone et al., 2001, [Long QT syndrome and Brugada syndrome: 2 aspects of the same disease?]., Ital Heart J Suppl
Shimizu et al., 2000, Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome., J. Cardiovasc. Electrophysiol.
Guo et al., 2006, Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin., Am. J. Physiol. Heart Circ. Physiol.
Krishnan et al., 1998, ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia., J. Cardiovasc. Electrophysiol.
Starmer et al., 1991, Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments., Circulation
Yang et al., 2010, Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal Na+ channels., Anesthesiology
Lipkind et al., 2010, Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore., Mol. Pharmacol.
Yang et al., 2002, Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker., Mol. Pharmacol.
Vohora et al., 2010, Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs., Drugs Today
Itoh et al., 2007, A paradoxical effect of lidocaine for the N406S mutation of SCN5A associated with Brugada syndrome., Int. J. Cardiol.
Fedida et al., 2006, The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers., J. Cardiovasc. Electrophysiol.
Wallace et al., 2006, Inhibition of cardiac voltage-gated sodium channels by grape polyphenols., Br. J. Pharmacol.
Karoly et al., 2010, Fast- or slow-inactivated state preference of Na+ channel inhibitors: a simulation and experimental study., PLoS Comput. Biol.
Muroi et al., 2009, Local anesthetics disrupt energetic coupling between the voltage-sensing segments of a sodium channel., J. Gen. Physiol.
Cerne et al., 2006, Pre-ovarian block versus paracervical block for oocyte retrieval., Hum. Reprod.
Louro et al., 1998, Carboxyl groups at the membrane interface as molecular targets for local anesthetics., Biophys. Chem.
Oka et al., 2002, Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade., Eur. J. Pharmacol.
Ryan et al., 1996, Structural effects of neutral and anionic lipids on the nicotinic acetylcholine receptor. An infrared difference spectroscopy study., J. Biol. Chem.
Fujiki et al., 2004, Repolarization abnormality in idiopathic ventricular fibrillation: assessment using 24-hour QT-RR and QaT-RR relationships., J. Cardiovasc. Electrophysiol.
Sugao et al., 2005, Repolarization dynamics in patients with idiopathic ventricular fibrillation: pharmacological therapy with bepridil and disopyramide., J. Cardiovasc. Pharmacol.
Antzelevitch, 2006, Brugada syndrome., Pacing Clin Electrophysiol
Satish et al., 2005, Brugada syndrome--an update., Chang Gung Med J
Wright et al., 1999, State-dependent cocaine block of sodium channel isoforms, chimeras, and channels coexpressed with the beta1 subunit., Biophys. J.
Brugada et al., 1999, [Brugada syndrome]., Arch Mal Coeur Vaiss
Brugada et al., 1999, The syndrome of right bundle branch block ST segment elevation in V1 to V3 and sudden death--the Brugada syndrome., Europace
Chen et al., 2000, Brugada syndrome without mutation of the cardiac sodium channel gene in a Taiwanese patient., J. Formos. Med. Assoc.
Weiss et al., 2002, Clinical and molecular heterogeneity in the Brugada syndrome: a novel gene locus on chromosome 3., Circulation
Brugada et al., 2000, Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts., Circulation
Wang et al., 2003, Effect of mexiletine on long QT syndrome model., Acta Pharmacol. Sin.
Valdivia et al., 2002, A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine., Cardiovasc. Res.
Fabritz et al., 2003, Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice., Cardiovasc. Res.
Chinushi et al., 2003, Ventricular tachyarrhythmias in a canine model of LQT3: arrhythmogenic effects of sympathetic activity and therapeutic effects of mexiletine., Circ. J.
Napolitano et al., 2006, Gene-specific therapy for inherited arrhythmogenic diseases., Pharmacol. Ther.
Thimann et al., 2012, Benzonatate toxicity in a teenager resulting in coma, seizures, and severe metabolic acidosis., J Pediatr Pharmacol Ther
Bishop-Freeman SC et al., 2017, Benzonatate Toxicity: Nothing to Cough At., J Anal Toxicol
Ahmmed et al., 2002, Analysis of moricizine block of sodium current in isolated guinea-pig atrial myocytes. Atrioventricular difference of moricizine block., Vascul. Pharmacol.
Weiss et al., 2010, Riluzole protects against cardiac ischaemia and reperfusion damage via block of the persistent sodium current., Br. J. Pharmacol.
Schwartz et al., 2002, Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole., Prog. Brain Res.
Song et al., 1997, Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels., J. Pharmacol. Exp. Ther.
Jaillon et al., 1989, Recent antiarrhythmic drugs., Am. J. Cardiol.
Holland et al., 1989, Indecainide: effects on arrhythmias, electrophysiology, and cardiovascular dynamics., J. Cardiovasc. Pharmacol.
Steinberg et al., Electrophysiological studies of indecainide hydrochloride, a new antiarrhythmic agent, in canine cardiac tissues., J. Cardiovasc. Pharmacol.
Kastrinsky DB et al., 2015, Reengineered tricyclic anti-cancer agents., Bioorg Med Chem
Napolitano et al., 2006, Brugada syndrome., Orphanet J Rare Dis
Tella et al., 1998, Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine., Pharmacol. Biochem. Behav.
Ohgo et al., 2007, Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation., Heart Rhythm
Stokoe et al., 2007, Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3., J. Physiol. (Lond.)
Sheets et al., 2010, Sodium channel molecular conformations and antiarrhythmic drug affinity., Trends Cardiovasc. Med.
Itoh et al., 2005, A novel missense mutation in the SCN5A gene associated with Brugada syndrome bidirectionally affecting blocking actions of antiarrhythmic drugs., J. Cardiovasc. Electrophysiol.
Grant, 2005, Electrophysiological basis and genetics of Brugada syndrome., J. Cardiovasc. Electrophysiol.
Edrich T et al., 2005, State-dependent block of human cardiac hNav1.5 sodium channels by propafenone., J Membr Biol
Mitiushin et al., 1978, [Several types of mitochondrial ultrastructure in animal cell mitochondria and their relationship to energy production]., Tsitologiia
Yang M et al., 2012, Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer., Breast Cancer Res Treat
Hasebe H et al., 2020, Pilsicainide Administration Unmasks a Phenotype of Brugada Syndrome in a Patient with Overlap Syndrome due to the E1784K SCN5A Mutation., Intern Med
Hale et al., 2006, Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit., J. Cardiovasc. Pharmacol. Ther.
Rajamani et al., Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine., Channels (Austin)
Sonsalla et al., 2010, The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance., Exp. Neurol.
Leppik, 2004, Zonisamide: chemistry, mechanism of action, and pharmacokinetics., Seizure
Sobieszek et al., Zonisamide: a new antiepileptic drug., Pol J Pharmacol
Kothare et al., 2008, Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety., Expert Opin Drug Metab Toxicol
Schulze-Bonhage, 2010, Zonisamide in the treatment of epilepsy., Expert Opin Pharmacother
Janszky, 2009, [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]., Ideggyogy Sz
Zaccara et al., 2009, Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature., Neuropsychiatr Dis Treat
Georgijević Milić, [Molecular genetics in the hereditary form of long QT syndrome]., Med. Pregl.

INDECAINIDE SCN5A

Interaction Score: 6.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
2688391 11752352 2476626 17016423 17139284 6206315

Sources:
TdgClinicalTrial TEND TTD
ENCAINIDE SCN5A

Interaction Score: 5.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
16751287 9835260 17016423 1653123 11752352

Sources:
TdgClinicalTrial TEND
BENZONATATE SCN5A

Interaction Score: 3.64

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
23258970 28334901

Sources:
TdgClinicalTrial TEND TTD
MEXILETINE SCN5A

Interaction Score: 2.67

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12676070 12123767 12650887 12604879 16168489 11752352 11196553

Sources:
TdgClinicalTrial TEND PharmGKB TTD
MORICIZINE SCN5A

Interaction Score: 2.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12402511 17016423 17139284 11752352

Sources:
TdgClinicalTrial TEND TTD
FOSPHENYTOIN SCN5A

Interaction Score: 2.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name fosphenytoin sodium injection,Cerebyx

PMIDs:
15001403 20298965 11752352 15066664

Sources:
TdgClinicalTrial TEND TTD
HEXYLCAINE SCN5A

Interaction Score: 2.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17016423 17139284 11752352

Sources:
TdgClinicalTrial TEND TTD
PROCAINAMIDE SCN5A

Interaction Score: 2.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10443304 11225790 11155778 11839626 11752352 10662748

Sources:
TdgClinicalTrial TEND PharmGKB
DISOPYRAMIDE SCN5A

Interaction Score: 1.94

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
15028073 11752352 15897781 11196553

Sources:
TdgClinicalTrial TEND PharmGKB TTD
FLECAINIDE SCN5A

Interaction Score: 1.75

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12601084 11535580 15272045 10758053 10617684 10961955 11752352 11307783 11196553

Sources:
TdgClinicalTrial TEND PharmGKB
TOCAINIDE SCN5A

Interaction Score: 1.45

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10953551 11752352

Sources:
TdgClinicalTrial TEND
DIBUCAINE SCN5A

Interaction Score: 1.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
9742684 12354567 8798723 11752352 17016423 17139284

Sources:
TdgClinicalTrial TEND TTD
APRINDINE SCN5A

Interaction Score: 1.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
1653644 1660104

Sources:
TdgClinicalTrial
QUINIDINE SCN5A

Interaction Score: 0.8

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
16972995 9476974 17556186 17023504 20685573 15877619 11752352 16138883

Sources:
TdgClinicalTrial TEND PharmGKB
LICARBAZEPINE SCN5A

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name licarbazepine , LIC-477

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
PILSICAINIDE SCN5A

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31484910

Sources:
PharmGKB
ETHOTOIN SCN5A

Interaction Score: 0.58

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
11752352 17016423 17139284 15066664

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
PROPAFENONE SCN5A

Interaction Score: 0.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name propafenone hydrochloride,Rythmol

Novel drug target Established target

PMIDs:
17016423 17139284 16463141

Sources:
TdgClinicalTrial TEND PharmGKB
RANOLAZINE SCN5A

Interaction Score: 0.52

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Ranexa

Novel drug target Established target

Mechanism of Interaction Sodium channel protein type V alpha subunit blocker

PMIDs:
17220471 19077543

Sources:
TdgClinicalTrial ChemblInteractions TEND
PRILOCAINE SCN5A

Interaction Score: 0.46

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

Trial Name Oraqix

PMIDs:
17016423 17139284 11752352

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
LIDOCAINE SCN5A

Interaction Score: 0.45

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name ALGRX 3268,Zingo

Novel drug target Established target

Trial Name lidocaine hydrochloride, piroxicam, AK1015,Akten

PMIDs:
17445919 16686685 17016511 20585544 19088384 16840798

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB
MEPHENYTOIN SCN5A

Interaction Score: 0.42

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Trial Name -

PMIDs:
15001403 11752352 15066664

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
FLECAINIDE ACETATE SCN5A

Interaction Score: 0.36

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel protein type V alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
RILUZOLE SCN5A

Interaction Score: 0.32

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name riluzole,Rilutek

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
20590601 12440368 17016423 17139284 9262334

Sources:
TdgClinicalTrial ChemblInteractions
ZONISAMIDE SCN5A

Interaction Score: 0.3

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Empatic

Novel drug target Established target

Trial Name OREX-003, olanzapine plus zonisamide SR

PMIDs:
19948168 15511691 14704463 18433351 20001433 20025128 19557119

Sources:
TdgClinicalTrial ChemblInteractions
AZD7009 SCN5A

Interaction Score: 0.24

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel protein type V alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LOMERIZINE SCN5A

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
OXCARBAZEPINE SCN5A

Interaction Score: 0.22

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

Novel drug target Established target

PMIDs:
20502724 17016423 17139284

Sources:
TdgClinicalTrial ChemblInteractions TEND
COCAINE SCN5A

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17038146 15880981 9876137

Sources:
TdgClinicalTrial TEND PharmGKB
TETRODOTOXIN SCN5A

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name tetrodotoxin,Tectin, Tetrodin

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD
DIBUCAINE HYDROCHLORIDE SCN5A

Interaction Score: 0.15

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel protein type V alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ESLICARBAZEPINE SCN5A

Interaction Score: 0.15

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Trial Name Eslicarbazepine

Novel drug target Established target

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions
BEPRIDIL SCN5A

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TEND
CARBAMAZEPINE SCN5A

Interaction Score: 0.13

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

Trial Name SPD 417, carbamazepine,Equetro, Carbatrol

PMIDs:
20526191 20643904 17016423 17139284 12391287

Sources:
TdgClinicalTrial ChemblInteractions TEND
AZD1305 SCN5A

Interaction Score: 0.12

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel protein type V alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CLOMIPRAMINE SCN5A

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26372073

Sources:
DTC
PHENYTOIN SCN5A

Interaction Score: 0.11

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
150666 15001403 22678159

Sources:
TdgClinicalTrial ChemblInteractions TEND
DYCLONINE SCN5A

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
MEXILETINE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TETRACAINE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CHLOROPROCAINE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
INDECAINIDE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ROPIVACAINE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PROCAINE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
QUINIDINE SULFATE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TOCAINIDE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
NKTR-171 SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PROCAINAMIDE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ESLICARBAZEPINE ACETATE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PROPOXYCAINE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
MERETHOXYLLINE PROCAINE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
MEPIVACAINE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LIDOCAINE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
QUINIDINE GLUCONATE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
EVENAMIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
HEXYLCAINE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PHENYTOIN SODIUM SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
ETIDOCAINE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
ARTICAINE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
QUINIDINE POLYGALACTURONATE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
FOSPHENYTOIN SODIUM SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
PROPARACAINE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
PHENACEMIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TETRACAINE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
BENOXINATE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
DISOPYRAMIDE PHOSPHATE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PRILOCAINE HYDROCHLORIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
RUFINAMIDE SCN5A

Interaction Score: 0.07

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
MORICIZINE HYDROCHLORIDE SCN5A

Interaction Score: 0.06

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
ERLOSAMIDE SCN5A

Interaction Score: 0.06

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
IRAMPANEL SCN5A

Interaction Score: 0.05

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PROPAFENONE HYDROCHLORIDE SCN5A

Interaction Score: 0.05

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
SAFINAMIDE SCN5A

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name Safinamide

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
PHENAZOPYRIDINE HYDROCHLORIDE SCN5A

Interaction Score: 0.05

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
DYCLONINE HYDROCHLORIDE SCN5A

Interaction Score: 0.05

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
DRONEDARONE HYDROCHLORIDE SCN5A

Interaction Score: 0.05

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
RALFINAMIDE SCN5A

Interaction Score: 0.04

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ORPHENADRINE HYDROCHLORIDE SCN5A

Interaction Score: 0.04

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
AMIODARONE SCN5A

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ORPHENADRINE CITRATE SCN5A

Interaction Score: 0.03

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LAMOTRIGINE SCN5A

Interaction Score: 0.03

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PRIMIDONE SCN5A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TOPIRAMATE SCN5A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LITHIUM SCN5A

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
NERISPIRDINE SCN5A

Interaction Score: 0.01

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions

Ensembl: ENSG00000183873
- Version: 101_38
Alternate Names:

SCN5A Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: Q14524
- Version: January-2014
Alternate Names:

SCN5A Gene Symbol

Gene Info:

Target Class Transporters

Target Subclass TC:1.A.1.10.3

Publications:
HopkinsGroom: Q14524
- Version: 11-September-2012
Alternate Names:

Q14524 Uniprot Accession

ENSG00000183873 Ensembl Gene Id

SCN5A Uniprot Gene Name

Gene Info:

Interpro Acc IPR005821

Interpro Type Domain

Interpro Name Ion transport domain

Gene Categories:

ION CHANNEL, DRUGGABLE GENOME

Publications:
BaderLabGenes: SCN5A
- Version: February-2014
Alternate Names:

6331 Entrez Gene ID

Gene Info:

Initial Gene Query Nav1.5

Counted Citations from 1950-2000 1178

Gene Categories:

ION CHANNEL

Publications:

RussLampel: ENSG00000183873

Version: 26-July-2011

Alternate Names:

SCN5A Display Id

ENSG00000183873 Ensembl Gene Id

SODIUM CHANNEL PROTEIN TYPE V ALPHA SUBUNIT (VOLTAGE-GATED SODIUM CHANNEL ALPHA SUBUNIT NAV1.5) (SODIUM CHANNEL PROTEIN, CARDIAC MUSCLE ALPHA-SUBUNIT) (HH1). [SOURCE:UNIPROT/SWISSPROT;ACC:Q14524] Description

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

TEND: Q14524
- Version: 01-August-2011
Alternate Names:

6331 Entrez Gene Id

Q14524 Uniprot Accession

SCN5A_HUMAN Uniprot Id

Gene Info:

Transmembrane Helix Count 22

Target Subclass Channels

Target Subclass Voltage_gated_ion_channels

Publications:
PharmGKB: SCN5A
- Version: 18-August-2020
Alternate Names:

PA304 PharmGKB ID

Gene Info:

Publications:

Hasebe H et al., 2020, Pilsicainide Administration Unmasks a Phenotype of Brugada Syndrome in a Patient with Overlap Syndrome due to the E1784K SCN5A Mutation., Intern Med
DTC: SCN5A
- Version: 02-September-2020
Alternate Names:

Gene Info:

Publications:

Kastrinsky DB et al., 2015, Reengineered tricyclic anti-cancer agents., Bioorg Med Chem
ChemblInteractions: SCN5A
- Version: chembl_23
Alternate Names:

SCN5A GENE_SYMBOL

Sodium channel protein type 5 subunit alpha UNIPROT

HH1 UNIPROT

Gene Info:

Publications:
HingoraniCasas: ENSG00000183873
- Version: 31-May-2017
Alternate Names:

ENSG00000183873 Gene Symbol

SCN5A Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
TTD: Voltage-gated sodium channel alpha Nav1.5
- Version: 2020.06.01
Alternate Names:

SCN5A TTD Gene Abbreviation

T39716 TTD Target ID

Gene Info:

Publications:
Pharos: SCN5A
- Version: 01-February-2022
Alternate Names:

Sodium channel protein type 5 subunit alpha Gene Name

Q14524 UniProt ID

Gene Info:

Gene Categories:

ION CHANNEL

Publications:
GO: SCN5A
- Version: 01-February-2022
Alternate Names:

Gene Info:

Gene Categories:

CELL SURFACE

Publications:

Novel drug target	Established target
Trial Name	fosphenytoin sodium injection,Cerebyx

Trial Name	licarbazepine , LIC-477
Novel drug target	Established target

Trial Name	propafenone hydrochloride,Rythmol
Novel drug target	Established target

Trial Name	Ranexa
Novel drug target	Established target
Mechanism of Interaction	Sodium channel protein type V alpha subunit blocker

Direct Interaction	yes
Mechanism of Interaction	Sodium channel alpha subunit blocker
Trial Name	Oraqix

Trial Name	ALGRX 3268,Zingo
Novel drug target	Established target
Trial Name	lidocaine hydrochloride, piroxicam, AK1015,Akten

Trial Name	Empatic
Novel drug target	Established target
Trial Name	OREX-003, olanzapine plus zonisamide SR

Trial Name	tetrodotoxin,Tectin, Tetrodin
Novel drug target	Established target

Trial Name	Eslicarbazepine
Novel drug target	Established target
Mechanism of Interaction	Sodium channel alpha subunit blocker

Q14524	Uniprot Accession
ENSG00000183873	Ensembl Gene Id
SCN5A	Uniprot Gene Name

blocker (inhibitory)
inhibitor (inhibitory)

SCN5A	Display Id
ENSG00000183873	Ensembl Gene Id
SODIUM CHANNEL PROTEIN TYPE V ALPHA SUBUNIT (VOLTAGE-GATED SODIUM CHANNEL ALPHA SUBUNIT NAV1.5) (SODIUM CHANNEL PROTEIN, CARDIAC MUSCLE ALPHA-SUBUNIT) (HH1). [SOURCE:UNIPROT/SWISSPROT;ACC:Q14524]	Description

6331	Entrez Gene Id
Q14524	Uniprot Accession
SCN5A_HUMAN	Uniprot Id

SCN5A	GENE_SYMBOL
Sodium channel protein type 5 subunit alpha	UNIPROT
HH1	UNIPROT

Sodium channel protein type 5 subunit alpha	Gene Name
Q14524	UniProt ID

SCN5A Gene Record

SCN5A 6331 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 2688391 11752352 2476626 17016423 17139284 6206315

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 16751287 9835260 17016423 1653123 11752352

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 23258970 28334901

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 12676070 12123767 12650887 12604879 16168489 11752352 11196553

Sources: TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 12402511 17016423 17139284 11752352

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name fosphenytoin sodium injection,Cerebyx

PMIDs: 15001403 20298965 11752352 15066664

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 17016423 17139284 11752352

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 10443304 11225790 11155778 11839626 11752352 10662748

Sources: TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name -

PMIDs: 15028073 11752352 15897781 11196553

Sources: TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 12601084 11535580 15272045 10758053 10617684 10961955 11752352 11307783 11196553

Sources: TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 10953551 11752352

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 9742684 12354567 8798723 11752352 17016423 17139284

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 1653644 1660104

Sources: TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name -

PMIDs: 16972995 9476974 17556186 17023504 20685573 15877619 11752352 16138883

Sources: TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Trial Name licarbazepine , LIC-477 Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31484910

Sources: PharmGKB

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs: 11752352 17016423 17139284 15066664

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name propafenone hydrochloride,Rythmol Novel drug target Established target

PMIDs: 17016423 17139284 16463141

Sources: TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name Ranexa Novel drug target Established target Mechanism of Interaction Sodium channel protein type V alpha subunit blocker

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
2688391 11752352 2476626 17016423 17139284 6206315

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
16751287 9835260 17016423 1653123 11752352

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
23258970 28334901

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12676070 12123767 12650887 12604879 16168489 11752352 11196553

Sources:
TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12402511 17016423 17139284 11752352

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name fosphenytoin sodium injection,Cerebyx

PMIDs:
15001403 20298965 11752352 15066664

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17016423 17139284 11752352

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10443304 11225790 11155778 11839626 11752352 10662748

Sources:
TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
15028073 11752352 15897781 11196553

Sources:
TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
12601084 11535580 15272045 10758053 10617684 10961955 11752352 11307783 11196553

Sources:
TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10953551 11752352

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
9742684 12354567 8798723 11752352 17016423 17139284

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
1653644 1660104

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
16972995 9476974 17556186 17023504 20685573 15877619 11752352 16138883

Sources:
TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name licarbazepine , LIC-477

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
31484910

Sources:
PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
11752352 17016423 17139284 15066664

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name propafenone hydrochloride,Rythmol

Novel drug target Established target

PMIDs:
17016423 17139284 16463141

Sources:
TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Ranexa

Novel drug target Established target

Mechanism of Interaction Sodium channel protein type V alpha subunit blocker

PMIDs:
17220471 19077543

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

Trial Name Oraqix

PMIDs:
17016423 17139284 11752352

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)